Renaissance Capital logo

I can see clearly now: Leading eyecare company Bausch + Lomb files for an estimated $3 billion dual listing in the US and Canada

January 13, 2022

Bausch + Lomb, a leading supplier of contact lenses and eyecare products, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. However, this is likely a placeholder for a deal we estimate could raise up to $3 billion. The company plans to dual list on the Toronto Stock Exchange.

Bausch + Lomb states that it is a leading global eye health company, with a presence in approximately 100 countries and a comprehensive portfolio of over 400 products, and is fully integrated and built to serve its customers across the full spectrum of their eye health needs. Its lines of business include vision care and consumer healthcare, ophthalmic pharmaceuticals, and surgical. Since 2017, Bausch + Lomb has introduced more than 260 new products in approximately 60 countries.

The Vaughan, Canada-based company was founded in 1853 and booked $3.7 billion in sales for the 12 months ended September 30, 2021. It plans to list on the NYSE under the symbol BLCO. Bausch + Lomb filed confidentially on May 27, 2021. Morgan Stanley, Goldman Sachs, Citi, J.P. Morgan, Barclays, BofA Securities, Guggenheim Securities, Jefferies, Evercore ISI, Wells Fargo Securities, and Deutsche Bank are the joint bookrunners on the deal. No pricing terms were disclosed.